1. 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. (December 2022) Authors: Baramidze, A.; Gogishvili, M.; Melkadze, T.; Giorgadze, D.; Penkov, K.D.; Makharadze, T.; Kalinka, E.; Nechaeva, M.; Laktionov, K.; Gessner, C.; Moreno Jaime, B.; Passalacqua, R.; Garassino, M.C.; Li, S.; Pouliot, J-F.; McGuire, K.; Quek, R.G.; Kaul, M.; Gullo, G.; Rietschel, P. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC. (December 2022) Authors: Cho, B.C.; Dy, G.; Kim, T.M.; Sarker, D.; Hamid, O.; Williamson, S.; Sang-We, K.; Hatim, H.; Chen, S.; Mani, J.; Jankovic, V.; Paccaly, A.J.; Masinde, S.; Lowy, I.; Brennan, L.; Gullo, G. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 150P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel) - Subgroup analysis. (December 2022) Authors: Hamid, O.; Lewis, K.; Weise, A.; McKean, M.; Papadopoulos, K.; Crown, J.P.; Thomas, S.; Kaczmar, J.; Lakhani, N.; Kim, T.M.; Kim, K.; Rabinowits, G.; Spira, A.S.; Mani, J.; Chen, S.; Gullo, G. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1). (December 2022) Authors: Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.; Tewari, K.S.; Monk, B.J.; de Melo, A.C.; Oaknin, A.; Li, S.; Gao, B.; Mathias, M.D.; Gullo, G.; Salvati, M.E.; Seebach, F.; Lowy, I.; Fury, M.; Rietschel, P. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1879 Impact of adjuvant trastuzumab (adjT) for early-stage (ES) breast cancer (BC) on clinical characteristics, survival and likelihood of durable complete response (DCR) of HER2-positive (HER2+) metastatic breast cancer (MBC): A 15-year single-institution cohort study. (September 2015) Authors: Zacchia, A.; Gullo, G.; Parker, I.; De Giorgi, A.; Fennelly, D.; Zanoni, D.; Walshe, J.; Defrein, A.M.; Quinn, C.; Silva, N.; O' Donovan, N.; Ballot, J.; Mc Dermott, E.; Crown, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S292 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 1939 Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant Doxorubicin: 10-Year follow-up. (September 2015) Authors: Murtagh, G.; O'Connell, E.; Lyons, T.; Ballot, J.; Jones, M.; Geraghty, L.; Gullo, G.; Crown, J.; McDonald, K.; Walsh, J.M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 1964 Pilot study of bevacizumab (Bev) in combination with docetaxel (T) and cyclophosphamide (C) as adjuvant treatment (AdjRx) for patients (pts) with early stage (ES) HER-2 normal breast cancer (BrCa) ICORG 08-10. (September 2015) Authors: Gullo, G.; Kennedy, J.; Breathnach, O.; McCaffrey, J.; Keane, M.; Martin, M.; Gupta, R.; Leonard, G.; Calvert, P.; Donnellan, P.; Walshe, J.; Mc Dermott, E.; Cairney, S.; Bose, R.; Scott, K.; Hernando, A.; Parker, I.; Tryfonopoulos, D.; Moulton, B.; Crown, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 239 Tyrosine kinase inhibitors (TKIs) enhance response to HER2 targeted antibodies. (September 2015) Authors: Ivers, L.; Collins, D.; Canonici, A.; Gullo, G.; O'Donovan, N.; Crown, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 3315 Pattern of systemic relapse and outcome of patients (pts) with ocular melanoma (OM) after curative local therapy (Rx): Results of an active surveillance strategy. (September 2015) Authors: Coleman, N.; Gullo, G.; Greally, M.; Kelly, C.; Power, B.; Kennedy, S.; Hoti, E.; Horgan, N.; Crown, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S669 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx). (February 2017) Authors: Gullo, G.; Walsh, N.; Zacchia, A.; Hammond, L.; Fennelly, D.; Walshe, J.; O'Mahony, K.; Maltese, M.; Crown, J. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗